Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Stock Jumped Today

By Keith Speights - May 4, 2020 at 4:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech stock bounced back quickly from Friday's sell-off, which followed the release of worse-than-expected first-quarter results.

What happened

Shares of ImmunoGen (IMGN 0.95%) closed Monday trading up 15.7%. The drugmaker reported first-quarter results on Friday that missed analysts' expectations, which sent shares into a slump. However, investors shrugged those results off Monday, and apparently focused instead on the potential for the company's lead candidate, mirvetuximab soravtansine.

So what

Quarterly results really don't matter that much for small biotechs like ImmunoGen. Its revenues primarily come from the royalties it receives from Roche from sales of breast cancer drug Kadcyla. But those royalties totaled only $13.3 million in the first quarter.

Female scientists in a lab

Image source: Getty Images.

What's more important for ImmunoGen is its pipeline progress. On that front, the drugmaker remains on track despite the COVID-19 pandemic. It initiated a pivotal late-stage study in the first quarter evaluating mirvetuximab as a treatment for ovarian cancer. It's also moving along with clinical trials of the drug in combination with other therapies.

CEO Mark Enyedy said in the company's Q1 conference call on Friday that ImmunoGen has plenty of inventory on hand to finish all of the ongoing clinical studies that include mirvetuximab. He also stated that the company has ample inventory to complete its phase 2 clinical studies evaluating IMGN532 and to conduct planned a planned phase 1 study for IMGC936. This was reassuring since some drugmakers have experienced supply chain disruptions due to the coronavirus outbreak.

Now what

The main things to watch with ImmunoGen are its upcoming presentations at scientific meetings, including one this month from a phase 2 study evaluating a combination of mirvetuximab and Avastin. In addition, the company plans to file for approval to begin a clinical study of IMGC936 by the end of the second quarter.

Good news from the Soraya late-stage study of mirvetuximab is the big catalyst for the biotech stock that investors are anxiously awaiting. However, it will be more than a year before the primary portion of that study wraps up. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$5.32 (0.95%) $0.05
Roche Holding AG Stock Quote
Roche Holding AG
$42.07 (1.25%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.